Innate Pharma Ownership | Who Owns Innate Pharma?
Innate Pharma Ownership Summary
Innate Pharma is owned by 0.12% institutional investors, and 99.88% retail investors. Morgan stanley is the largest institutional shareholder, holding 0.05% of IPHA shares. Range Cancer Therapeutics ETF is the top mutual fund, with 0.07% of its assets in Innate Pharma shares.
IPHA Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Innate Pharma | 0.12% | - | 99.88% |
| Sector | Healthcare Stocks | 488.30% | 11.08% | -399.38% |
| Industry | Biotech Stocks | 307.10% | 11.11% | -218.21% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Morgan stanley | 43.52K | 0.05% | $84.44K |
| Citadel advisors | 23.53K | 0.03% | $45.64K |
| Millennium management | 15.33K | 0.02% | $27.28K |
| Ubs group | 3.51K | 0.00% | $6.46K |
| Gamma investing | 2.28K | 0.00% | $4.40K |
| Rhumbline advisers | 675.00 | 0.00% | $1.25K |
| Barclays | 307.00 | 0.00% | $1.00K |
| Principal securities | 45.00 | 0.00% | $82.00 |
| Optiver b.v. | 101.00 | 0.00% | $177.00 |
| Exchange traded concepts | - | - | - |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Gamma investing | 2.28K | 0.00% | $4.40K |
| Tower research capital llc (trc) | - | - | - |
| Barclays | 307.00 | - | $1.00K |
| Optiver b.v. | 101.00 | - | $177.00 |
| Steward partners investment advisory | - | - | - |
| Jane street group | - | - | - |
| Rhumbline advisers | 675.00 | - | $1.25K |
| Millennium management | 15.33K | - | $27.28K |
| Ubs group | 3.51K | - | $6.46K |
| Citadel advisors | 23.53K | - | $45.64K |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Citadel advisors | 23.53K | - | 23.53K |
| Millennium management | 15.33K | - | 15.33K |
| Rhumbline advisers | 675.00 | - | 470.00 |
| Principal securities | 45.00 | - | 45.00 |
| Farther finance advisors | 10.00 | - | 10.00 |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Exchange traded concepts | - | - | -62.75K |
| Jane street group | - | - | -14.55K |
| Ubs group | 3.51K | - | -4.90K |
| Gamma investing | 2.28K | 0.00% | -1.18K |
| Morgan stanley | 43.52K | - | -600.00 |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Citadel advisors | 23.53K | - | 23.53K | $45.64K |
| Millennium management | 15.33K | - | 15.33K | $27.28K |
| Principal securities | 45.00 | - | 45.00 | $82.00 |
| Farther finance advisors | 10.00 | - | 10.00 | $19.00 |
Sold Out
| Holder | Change |
|---|---|
| Tower research capital llc (trc) | -3.00 |
| Steward partners investment advisory | -200.00 |
| National bank of canada /fi/ | -450.00 |
| Jane street group | -14.55K |
| Exchange traded concepts | -62.75K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | 9 | -10.00% | 99,838 | -36.89% | - | 323.31% | 4 | -20.00% | 3 | 200.00% |
| Mar 31, 2025 | 1 | -88.89% | 15,326 | -88.89% | - | 64.33% | 1 | -50.00% | - | -100.00% |
| Dec 31, 2024 | 5 | -37.50% | 78,982 | -66.82% | - | 111.34% | 2 | 100.00% | - | -100.00% |
| Sep 30, 2024 | 8 | - | 238,049 | -1.53% | - | 330.02% | 1 | -66.67% | 4 | 100.00% |
| Jun 30, 2024 | 8 | -11.11% | 241,754 | -4.79% | - | 301.68% | 3 | -25.00% | 2 | - |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Range Cancer Therapeutics ETF | 62.75K | 0.07% | - |
| ActivePassive International Equity ETF | 37.49K | 0.05% | 132.00 |
IPHA Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools